Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), recently executed a series of transactions involving the company's stock. On February 12, Dickinson sold 137,676 ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Thousands of protesters have gathered in central London for a march supporting Tommy Robinson - alongside a separate counter-demonstration. The "Stop the Isolation" or "Unite the Kingdom" rally ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $105.00. The company’s shares closed yesterday at $96.95.

And we know the phone signal in London is awful right now, but things could be looking up, because soon a free wi-fi network will be launched across central London. Westminster City Council ...

TEANECK, N.J., Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims ...

Our teaching excellence feeds into a fantastic array of undergraduate degrees in a variety of subjects, while our ground-breaking research has led to: new treatments for ovarian cancer, the discovery ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the trades showed up on publicly ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released on ...